Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01277302 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
A Phase 4 study of Macular Edema, sponsored by Genentech.
- Completed
- Registry status
- Phase 4
- Development phase
- 202
- Enrollment target
- 20
- Study locations
NCT01277302 is a Phase 4 study of Macular Edema that has completed, run by Genentech. The registered enrollment target is 202 participants, above the 165-participant average among 14 other Macular Edema trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT01277302, a Phase 4 study of Macular Edema, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 202 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (20)
California
- - Beverly Hills
- - Chico
- - Mountain View
- - Oakland
- - San Francisco
- - Santa Ana
- - Santa Barbara
- - Torrance
Florida
- - Altamonte Springs
- - Boynton Beach
- - Lakeland
Arizona
- - Phoenix
- - Tucson
Colorado
- - Colorado Springs
- - Golden
Maryland
- - Baltimore
- - Hagerstown
Connecticut
- - New London
Georgia
- - Augusta
Illinois
- - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01277302
The ClinicalTrials.gov registry entry for NCT01277302 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 165-participant average among 14 other Macular Edema trials with a reported enrollment target (22% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01277302 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01277302 about?
NCT01277302 is a clinical study titled "A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion". This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).
What is the current status of trial NCT01277302?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 202 participants. The study started on 2011-02. Estimated completion is 2012-10.
What conditions does trial NCT01277302 study?
This clinical trial studies the following conditions: Macular Edema.
What interventions are being tested in trial NCT01277302?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01277302?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01277302 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
RECRUITING · Phase 2
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
COMPLETED · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
COMPLETED · Phase 3
-
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.